# Alcohol consumption with semaglutide

> Alcohol studies at Wellness Clinics America — Wellness Clinics America considers a small semaglutide trial in alcohol use disorder: laboratory consumption, heavy drinking and a larger study’s questions.

A small trial in adults with alcohol use disorder concerns alcohol consumed in a laboratory task and heavy drinking over follow-up.

## A trial with 48 adults

A [phase 2 randomised trial enrolled 48 adults with alcohol use disorder](https://pubmed.ncbi.nlm.nih.gov/39937469/). Low-dose semaglutide reduced laboratory alcohol self-administration, measured in grams consumed, and predicted greater reductions in heavy drinking over 9 weeks versus placebo. The trial’s diagnosis and size set a very different scene from the large cardiovascular studies.

The laboratory task appeals to my appetite for concrete observations. Measuring alcohol consumed gives a concrete subject to a conversation that can drift toward vague claims about wanting less. The task and the follow-up drinking findings deserve attention for what they address, while sustained recovery remains a further question I’d want a future investigation to put at its centre.

This is an early human trial with a small group. Both the experiment and its findings excite me; it would take a fuller clinical record to support a broad account of treatment for alcohol use disorder.

![Gouache of an amber drink and water on a café table](images/alcohol-task.webp)

*An editorial still life about consumption, not a reconstruction of the laboratory task.*

## Laboratory consumption and heavy drinking

The [trial report distinguishes the alcohol consumed in a self-administration task from predicted greater reductions in heavy drinking over follow-up](https://pubmed.ncbi.nlm.nih.gov/39937469/). The task result and the drinking findings concern related behaviours, observed in different settings. I prefer having both in the conversation to allowing either one to stand for everything about a drinking problem.

The diagnosis alcohol use disorder gives this page its subject. A result among those participants raises questions about later trials with different treatment goals, levels of severity and follow-up periods. Those are questions, not a description of differences this report has already resolved.

The useful surprise is that semaglutide can be investigated around a problem other than body weight. That expands the research conversation without making the weight-loss trials into evidence about drinking. The participants and the measurements have changed.

## The limit of the connection

The [heart trials](/heart) and [kidney trial](/kidney) put serious clinical events at the centre of much larger studies. This alcohol trial asks a smaller, earlier question about consumption. Its place in the collection comes from that specificity.

The trial enrolled 48 adults with alcohol use disorder. Its consumption findings do not show how drinking changes relate to the heart, kidney or liver outcomes in the other reports. Those possible connections intrigue me, but the separate studies cannot supply them. A larger, longer investigation could give the next account firmer ground.

---

Wellness Clinics America is my research reading room, where published research gets a closer look at its participants; this is not a clinic or a business, and none of it is medical advice.